These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33245754)

  • 1. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
    Mancia G
    Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
    Tadic M; Cuspidi C
    J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351
    [No Abstract]   [Full Text] [Related]  

  • 4. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
    Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
    Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
    J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore.
    Saavedra JM
    Physiology (Bethesda); 2021 May; 36(3):160-173. PubMed ID: 33904788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients.
    Harky A; Chor CYT; Nixon H; Jeilani M
    J Renin Angiotensin Aldosterone Syst; 2021; 22(1):1470320320987118. PubMed ID: 33412991
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
    Suh SH; Ma SK; Kim SW; Bae EH
    Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.
    Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F
    Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19 Population.
    Sattar Y; Mukuntharaj P; Zghouzi M; Suleiman AM; Attique H; Ullah W; Sana MK; Zaher N; Mehmood M; Doshi RP; Panchal A; Mir T; Nadeem M; Ali OE; Mohamed M; Bagur R; Elgendy IY; Mamas MA; Alraies MC
    High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):405-416. PubMed ID: 34181203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.
    Ferrara F; Vitiello A
    Cardiovasc Toxicol; 2021 Jun; 21(6):498-503. PubMed ID: 33835386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox.
    Javanmard SH; Heshmat-Ghahdarijani K; Vaseghi G
    Infect Control Hosp Epidemiol; 2021 Jan; 42(1):118-119. PubMed ID: 32362297
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension.
    Meng X; Liu Y; Wei C; Zhang K; Zhang Y; Zhong M; Zhang C; Zhang Y
    Sci China Life Sci; 2021 May; 64(5):836-839. PubMed ID: 32975722
    [No Abstract]   [Full Text] [Related]  

  • 17. ACE2: from protection of liver disease to propagation of COVID-19.
    Warner FJ; Rajapaksha H; Shackel N; Herath CB
    Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The concern about ACE/ARB and COVID-19: Time to hold your horses!
    Pergolizzi JV; Varrassi G; Magnusson P; LeQuang JA; Leopoulou M; Paladini A; Taylor R; Wollmuth C; Breve F;
    J Am Pharm Assoc (2003); 2020; 60(6):e88-e90. PubMed ID: 32747165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renin-angiotensin-aldosterone system inhibitors in COVID-19: from acidosis to ventilation and immunity.
    Liao WH; Yang GG; Henneberg M
    Swiss Med Wkly; 2020 Nov; 150():w20444. PubMed ID: 33306813
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential Roles of the Renin-Angiotensin System in the Pathogenesis and Treatment of COVID-19.
    Lu L; Liu X; Jin R; Guan R; Lin R; Qu Z
    Biomed Res Int; 2020; 2020():7520746. PubMed ID: 33204713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.